Why Choose GALEAS™ Bladder?

Ultra-Sensitive Detection

Identifies somatic mutations across 23 genes present in over 96% of bladder cancer cases

Non-Invasive

Simple urine-based test eliminates unnecessary invasive procedures like cystoscopy

Utilized Across Study Cohorts

Tested on 710 urine samples across three UK clinical cohorts, ensuring high accuracy and reliability

Comprehensive Reporting

Provides detailed somatic variant analysis and positive/negative results

Watch the GALEAS™ Bladder Video Introduction

Performance Data

GALEAS™ Bladder delivers exceptional performance across all stages and grades of bladder cancer:

	Sensitivity	Specificity	NPV
pTa	89%	86%	99%
T1	97%	86%	99%
T2+	92%	86%	99%
G1	78%	86%	99%
G2	93%	86%	99%
G3	96%	86%	99%
NMIBC	92%	86%	99%
MIBC	92%	86%	99%

GALEAS™ Bladder for Hematuria Triage

Each year, hundreds of thousands of patients with hematuria (blood in urine) undergo invasive cystoscopy procedures, yet only about 10% are diagnosed with bladder cancer. GALEAS™ Bladder offers a non-invasive molecular triage solution, reducing unnecessary procedures and associated costs while providing rapid and accurate results.

How Does GALEAS™ Bladder Support Diagnosis?

Reporting

• A positive/negative report will be sent to the urologist
• Details of somatic variants identified are provided

Cloud-Based GALEAS™ Analysis Software

The GALEAS™ platform provides:

• Simple positive/negative results
• Detailed somatic variant analysis
• Secure, cloud-based accessibility for seamless integration into clinical workflows

Urologist requests a urine collection device for patient

Patient sends barcoded urine sample to service laboratory

Lab uploads sequencing results to secure cloud-based GALEAS platform

Results analyzed, report generated and shared directly with urologist

Urologist shares results with patient and discusses next steps

References

1.  Zhu, C. Z., Ting, H. N., Ng, K. H., & Ong, T. A. (2019). A review on the accuracy of bladder cancer detection methods. Journal of cancer, 10(17), 4038. Full article

2. Alimi, Q., Hascoet, J., Manunta, A., Kammerer‐Jacquet, S. F., Verhoest, G., Brochard, C., … & Peyronnet, B. (2018). Reliability of urinary cytology and cystoscopy for the screening and diagnosis of bladder cancer in patients with neurogenic bladder: a systematic review. Neurourology and Urodynamics, 37(3), 916-925. Full article

3. Ward et al. BJU Int. 2019, Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification

3. Ward DG, Gordon NS, Boucher RH, et al. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. BJU Int. 2019;124(3):532-544. doi:10.1111/BJU.14808. Full article